<~-- -->
Clinical Research Advantage, Inc.
, (CRA), a provider of a range of research services to pharmaceutical companies and clinical research organizations (CROs), announced its expansion into the Colorado Springs market with the opening of two local area offices.
CRA has forged a partnership with a medical practice in the area whose physicians serve as principal investigators of the clinical trials it manages and oversees. As a trial management organization (TMO), CRA helps clinical trial sponsors bring drugs to market more quickly and efficiently. CRA offers a mechanism for medical professionals to conduct phase II-IV clinical research trials. CRA is comprised of dozens of community-based investigators based throughout the country.
Local CRA offices in Colorado Springs include one at Colorado Springs Health Partners in Briargate—2405 Research Parkway in Briargate (office of Kari Uusinarkaus, M.D.; Dennis Schneider, M.D. and Gordon Golden, M.D.); and on the east side at 6340 Barnes Road (office of John Speer, M.D., Max Nevarez, M.D., Royce Solano, M.D. and Alan Garscadden, M.D.).
Current plans call for several more sites to open in the Colorado Springs area by summer 2011.
The new offices and principal investigators focus on trials and maintenance studies relating to the various diagnoses as well as others within the realm of family and internal medicine. At Briargate, studies underway include irritable bowel syndrome-diarrhea, hypercholesterolemia, Type II Diabetes Naïve (not currently being treated with anti-diabetic medication) and acute coronary syndrome with or without Type II Diabetes. Upcoming studies include Type II Diabetes and hypertriglyceridemia. At the east office, studies being conducted include those for chronic obstructive pulmonary disease, irritable bowel syndrome-diarrhea, pediatric influenza vaccine, and Type II Diabetes with cardiovascular risk. Upcoming studies at this office include opioid-induced constipation and Type II diabetes.
Concurrent with the office openings, CRA named Monica Garcia, BS, CCRC, to the post of region manager. Garcia heads the Colorado Springs-area operations and has worked with CRA for the past six years. She is certified through the Association of Clinical Research Professionals , an industry trade organization that serves as a resource for clinical research professionals engaged in the pharmaceutical, biotechnology and medical device industries, and those in hospital, academic medical centers and physician office settings.
Since CRA was acquired in 2007 by Mark Hanley, who serves as chief executive officer, and David Bruggeman, president and chief operating officer, the company has grown from six to 23 sites, doubled the number of employees and substantially increased the revenue base.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.